Compugen Ltd (NASDAQ:CGEN) reported encouraging data from their studies on COM701, COM902, and pembrolizumab in patients with ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Reports Q3 revenue $17.1M, consensus $17.86M. Compugen (CGEN) expects that its cash and cash related balances will be sufficient to fund its ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in ...

"A highlight of the third quarter was the presentation of our validating COM701, COM902, pembrolizumab combination data in heavily pre-treated platinum resistant ovarian cancer (PROC) patients at SITC ...

AN orange zombie fungus that sprouts from the backs of caterpillars could be used to fight cancer, new research suggests. Scientists have found the fungus, called Cordyceps, works by stopping cell ...

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., ...

While Lynparza is already used to treat BRCA-positive ovarian cancer, AZ specifically excluded ... (atezolizumab), Merck & Co’s Keytruda (pembrolizumab), and Bristol-Myers Squibb’s Opdivo ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

The companies are chasing the valuable first-line lung cancer therapy that Merck’s Keytruda (pembrolizumab ... gastric cancer, and ovarian cancer. AZ is prioritising its durvalumab, a rival ...